Takeda Strengthens Patient Offering In India Via Availability Of Vedolizumab (Kynteles®) - GADGET-INNOVATIONS

GADGET-INNOVATIONS

Updates On Latest Technology, Innovations, Apps, Softwares, Mobiles, Computing, Gadgets, Appliances, Fashion, Healthcare, Auto & Many Others......

Post Top Ad

Takeda Strengthens Patient Offering In India Via Availability Of Vedolizumab (Kynteles®)

Share This





· Introduces innovative Gastrointestinal portfolio for patients with Inflammatory Bowel Diseases (IBD) and Ulcerative Colitis and Crohn's Disease

· Kynteles® is likely to benefit patients with a low risk of serious or opportunistic infections like Tuberculosis

· Current disease burden for IBD is over 1.5 million in India



Takeda India, part of the Takeda Pharmaceutical Company Limited, a global values-based R&D-driven biopharmaceutical leader, today announced the expansion of its highly innovative portfolio for patients in the country with the launch of Kynteles® (generic name: Vedolizumab) as part of its Gastrointestinal (GI) portfolio. GI is Takeda's second therapeutic area in India after Rare Diseases (Haematology, Genetic Diseases, and Immunology).


Kynteles® is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn's Disease (CD). Kynteles®, more widely known as Entvyio®, has shown favourable safety and efficacy results in treating patients suffering from moderate to severe IBD.


Speaking about the launch, Koki Sato, Country Head, Takeda India, said, "At Takeda, we are continuously working towards developing innovative medicines to considerably improve the quality of life of patients. The launch of our highly innovative GI portfolio is a testimony of our commitment to India and patients living with diseases like UC and CD. Patient access to Kynteles® will further augment our vision of providing additional and innovative treatment options to HCPs treating UC and CD."


Both UC and CD are chronic idiopathic Inflammatory Bowel Diseases that can be debilitating and sometimes lead to life-threatening complications and require life-long disease management. Therefore, their treatments involve ensuring long-term remission with a proven safety profile. Entyvio® is currently marketed in more than 60 countries. In just five years since its global launch, Entyvio® has touched over 415,000 cumulative patient-years of experience.



There are currently over 1.5 million IBD patients in India.





New Delhi, INDIA, July 08, 2020







Youtube

Post Bottom Ad